## J R Fraser Cummings

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7017518/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Association scan of 14,500 nonsynonymous SNPs in four diseases identifies autoimmunity variants. Nature Genetics, 2007, 39, 1329-1337.	21.4	1,298
2	Sequence variants in the autophagy gene IRGM and multiple other replicating loci contribute to Crohn's disease susceptibility. Nature Genetics, 2007, 39, 830-832.	21.4	1,063
3	Predictors of anti-TNF treatment failure in anti-TNF-naive patients with active luminal Crohn's disease: a prospective, multicentre, cohort study. The Lancet Gastroenterology and Hepatology, 2019, 4, 341-353.	8.1	431
4	Genetic determinants of ulcerative colitis include the ECM1 locus and five loci implicated in Crohn's disease. Nature Genetics, 2008, 40, 710-712.	21.4	403
5	The pattern and outcome of acute severe colitis. Journal of Crohn's and Colitis, 2010, 4, 431-437.	1.3	276
6	Th17 Cells Expressing KIR3DL2+ and Responsive to HLA-B27 Homodimers Are Increased in Ankylosing Spondylitis. Journal of Immunology, 2011, 186, 2672-2680.	0.8	260
7	HLA-DQA1*05 Carriage Associated With Development of Anti-Drug Antibodies to Infliximab and Adalimumab in Patients With Crohn's Disease. Gastroenterology, 2020, 158, 189-199.	1.3	249
8	Infliximab is associated with attenuated immunogenicity to BNT162b2 and ChAdOx1 nCoV-19 SARS-CoV-2 vaccines in patients with IBD. Gut, 2021, 70, 1884-1893.	12.1	233
9	IL23R Variation Determines Susceptibility But Not Disease Phenotype in Inflammatory Bowel Disease. Gastroenterology, 2007, 132, 1657-1664.	1.3	170
10	HLA-DQA1–HLA-DRB1 variants confer susceptibility to pancreatitis induced by thiopurine immunosuppressants. Nature Genetics, 2014, 46, 1131-1134.	21.4	165
11	QT and QTc dispersion are accurate predictors of cardiac death in newly diagnosed non-insulin dependent diabetes: cohort study. BMJ: British Medical Journal, 1998, 316, 745-746.	2.3	122
12	Biosimilar Infliximab in Inflammatory Bowel Disease: Outcomes of a Managed Switching Programme. Journal of Crohn's and Colitis, 2017, 11, jjw216.	1.3	118
13	Confirmation of the role of ATG16l1 as a Crohn's disease susceptibility gene. Inflammatory Bowel Diseases, 2007, 13, 941-946.	1.9	98
14	Mercaptopurine versus placebo to prevent recurrence of Crohn's disease after surgical resection (TOPPIC): a multicentre, double-blind, randomised controlled trial. The Lancet Gastroenterology and Hepatology, 2016, 1, 273-282.	8.1	91
15	Clinical Features and HLA Association of 5-Aminosalicylate (5-ASA)-induced Nephrotoxicity in Inflammatory Bowel Disease. Journal of Crohn's and Colitis, 2016, 10, 149-158.	1.3	85
16	Contribution of the novel inflammatory bowel disease gene IL23R to disease susceptibility and phenotype. Inflammatory Bowel Diseases, 2007, 13, 1063-1068.	1.9	81
17	Oral methotrexate in ulcerative colitis. Alimentary Pharmacology and Therapeutics, 2005, 21, 385-389.	3.7	75
18	Human Intestinal Macrophages Are Involved in the Pathology of Both Ulcerative Colitis and Crohn Disease. Inflammatory Bowel Diseases, 2021, 27, 1641-1652.	1.9	62

J R FRASER CUMMINGS

#	Article	IF	CITATIONS
19	Consensus standards of healthcare for adults and children with inflammatory bowel disease in the UK. Frontline Gastroenterology, 2020, 11, 178-187.	1.8	59
20	Killer Ig-like receptor (KIR) genotype and HLA ligand combinations in ulcerative colitis susceptibility. Genes and Immunity, 2006, 7, 576-582.	4.1	58
21	The genetics of NOD-like receptors in Crohn's disease. Tissue Antigens, 2010, 76, 48-56.	1.0	56
22	Thiopurine withdrawal during sustained clinical remission in inflammatory bowel disease: relapse and recapture rates, with predictive factors in 237 patients. Alimentary Pharmacology and Therapeutics, 2014, 40, 1313-1323.	3.7	55
23	Medical management of Crohn's disease. BMJ: British Medical Journal, 2008, 336, 1062-1066.	2.3	52
24	MicroRNA-31 and MicroRNA-155 Are Overexpressed in Ulcerative Colitis and Regulate IL-13 Signaling by Targeting Interleukin 13 Receptor α-1. Genes, 2018, 9, 85.	2.4	49
25	Abnormal Insulin Treatment Behaviour: a Major Cause of Ketoacidosis in the Young Adult. Diabetic Medicine, 1995, 12, 429-432.	2.3	41
26	Clinical and molecular characteristics of isolated colonic Crohn's disease. Inflammatory Bowel Diseases, 2008, 14, 1667-1677.	1.9	38
27	Adalimumab Biosimilars in Europe: An Overview of the Clinical Evidence. BioDrugs, 2019, 33, 241-253.	4.6	34
28	Improving outpatient services: the Southampton IBD virtual clinic. Postgraduate Medical Journal, 2012, 88, 487-491.	1.8	32
29	Life in lockdown: experiences of patients with IBD during COVID-19. BMJ Open Gastroenterology, 2020, 7, e000541.	2.7	32
30	Review article: treatingâ€ŧoâ€ŧarget for inflammatory bowel diseaseâ€associated anaemia. Alimentary Pharmacology and Therapeutics, 2018, 48, 610-617.	3.7	28
31	Early real-world effectiveness of ustekinumab for Crohn's disease. Frontline Gastroenterology, 2020, 11, 111-116.	1.8	28
32	JAK1 inhibition and inflammatory bowel disease. Rheumatology, 2021, 60, ii45-ii51.	1.9	27
33	Association between genetic variants in myosin IXB and Crohn's disease. Inflammatory Bowel Diseases, 2009, 15, 1014-1021.	1.9	25
34	Two-stage candidate gene study of chromosome 3p demonstrates an association between nonsynonymous variants in the MST1R gene and Crohn's disease. Inflammatory Bowel Diseases, 2008, 14, 500-507.	1.9	24
35	Clinical Implications of Inflammatory Bowel Disease Genetics on Phenotype. Inflammatory Bowel Diseases, 2005, 11, 56-61.	1.9	23
36	Transitioning from Intravenous to Subcutaneous Vedolizumab in Patients with Inflammatory Bowel Disease [TRAVELESS]. Journal of Crohn's and Colitis, 2022, 16, 911-921.	1.3	21

J R FRASER CUMMINGS

#	Article	IF	CITATIONS
37	Nutrition and inflammatory bowel disease. Current Opinion in Clinical Nutrition and Metabolic Care, 2011, 14, 491-496.	2.5	18
38	Improving outpatient services: the Southampton IBD virtual clinic. Frontline Gastroenterology, 2012, 3, 76-80.	1.8	18
39	MicroRNAs in Inflammatory Bowel Diseases. Inflammatory Bowel Diseases, 2015, 21, 1160-1165.	1.9	18
40	Innovative approaches to biologic development on the trail of CT-P13: biosimilars, value-added medicines, and biobetters. MAbs, 2021, 13, 1868078.	5.2	17
41	Consensus recommendations for patient-centered therapy in mild-to-moderate ulcerative colitis: the i Support Therapy–Access to Rapid Treatment (iSTART) approach. Intestinal Research, 2018, 16, 522-528.	2.6	17
42	Anti-TNF biosimilars in Crohn's Disease: a patient-centric interdisciplinary approach. Expert Review of Gastroenterology and Hepatology, 2019, 13, 731-738.	3.0	16
43	Nationwide improvement in outcomes of emergency admission for ulcerative colitis in England, 2005â€2013. Alimentary Pharmacology and Therapeutics, 2019, 50, 176-192.	3.7	15
44	Association of <i>caspaseâ€9</i> and <i>RUNX3</i> with inflammatory bowel disease. Tissue Antigens, 2011, 77, 23-29.	1.0	14
45	MicroRNA-31 Targets Thymic Stromal Lymphopoietin in Mucosal Infiltrated CD4+ T Cells: A Role in Achieving Mucosal Healing in Ulcerative Colitis?. Inflammatory Bowel Diseases, 2018, 24, 2377-2385.	1.9	12
46	High incidence of glucocorticoid-induced hyperglycaemia in inflammatory bowel disease: metabolic and clinical predictors identified by machine learning. BMJ Open Gastroenterology, 2020, 7, e000532.	2.7	10
47	Clinical Features and Genetic Risk of Demyelination Following Anti-TNF Treatment. Journal of Crohn's and Colitis, 2020, 14, 1653-1661.	1.3	9
48	The impact of an inflammatory bowel disease nurse-led biologics service. Frontline Gastroenterology, 2016, 7, 283-288.	1.8	8
49	MicroRNA23a Overexpression in Crohn's Disease Targets Tumour Necrosis Factor Alpha Inhibitor Protein 3, Increasing Sensitivity to TNF and Modifying the Epithelial Barrier. Journal of Crohn's and Colitis, 2020, 14, 381-392.	1.3	8
50	A Systematic Review on Infliximab Biosimilar SB2: From Pre-Clinical Data to Real-World Evidence. Expert Opinion on Biological Therapy, 2022, 22, 203-223.	3.1	8
51	Enhancing treatment success in inflammatory bowel disease: Optimising the use of anti-TNF agents and utilising their biosimilars in clinical practice. Digestive and Liver Disease, 2020, 52, 1259-1265.	0.9	7
52	Hypopituitarism following Coronary Artery Bypass Surgery. Scottish Medical Journal, 1997, 42, 116-117.	1.3	6
53	Ferric maltol Real-world Effectiveness Study in Hospital practice (FRESH): clinical characteristics and outcomes of patients with inflammatory bowel disease receiving ferric maltol for iron-deficiency anaemia in the UK. BMJ Open Gastroenterology, 2021, 8, e000530.	2.7	6
54	A retrospective observational study of early experiences of vedolizumab treatment for inflammatory bowel disease in the UK. Medicine (United States), 2019, 98, e14681.	1.0	5

J R FRASER CUMMINGS

#	Article	lF	CITATIONS
55	Tuberculosis and TNF-inhibitors: history of exposure should outweigh investigations. BMJ Case Reports, 2014, 2014, bcr2013202127-bcr2013202127.	0.5	5
56	Inflammatory bowel disease registries for collection of patient iron parameters in Europe. World Journal of Gastroenterology, 2018, 24, 1063-1071.	3.3	4
57	Impact of direct-access IBD physician delivered endoscopy on clinical outcomes: a pre-implementation and post-implementation study. Frontline Gastroenterology, 2022, 13, 477-483.	1.8	2
58	Sa1196 Prospective, Randomized, Double-Blind, Sham-Treatment Controlled Multi-Center Study to Evaluate Efficacy and Safety of Leukocytapheresis (LCAP) Using ACD-A As Anticoagulant in Patients With Steroid-Free, Active Ulcerative Colitis. Gastroenterology, 2013, 144, S-226.	1.3	1
59	Su1228 Thiopurine Withdrawal for Sustained Remission in IBD: A UK Multicentre Study. Gastroenterology, 2013, 144, S-433-S-434.	1.3	1
60	Editorial: CTâ€P13, a biosimilar of antiâ€ŧumour necrosis factorâ€alpha agent (infliximab), in inflammatory bowel diseases. Alimentary Pharmacology and Therapeutics, 2017, 45, 1370-1371.	3.7	1
61	Roundtable on registries: practical considerations for registries – making them work, London, UK, 26 January 2017. GaBI Journal, 2017, 6, 122-134.	0.3	1
62	The effects of an integrated education programme on the management of diabetic ketoacidosis. Practical Diabetes International: the International Journal for Diabetes Care Teams Worldwide, 1995, 12, 235-237.	0.2	0
63	298 The Genetics of Nod-like Receptor Proteins in Crohn's Disease. Gastroenterology, 2008, 134, A-42.	1.3	Ο
64	W1257 The Arg381gln SNP in IL 23 R Does Not Influence Response to Immunomodulators in Ulcerative Colitis or Crohn's Disease. Gastroenterology, 2008, 134, A-666.	1.3	0
65	W1258 The Combined Effect of the Aicartase C347g and the Aldehyde Oxidase A3505g SNPs Predict Efficacy of Methotrexate Therapy in Inflammatory Bowel Disease. Gastroenterology, 2008, 134, A-666.	1.3	0
66	W1847 Prevalence and Determinants of PSC in a Cohort of Patients with Inflammatory Bowel Disease and Normal Liver Function Tests. Gastroenterology, 2008, 134, A-837.	1.3	0
67	S1132 Neoplasia Within 10 Years of Diagnosis of Ulcerative Colitis. Gastroenterology, 2009, 136, A-196.	1.3	Ο
68	S1142 The Pattern and Outcome of Acute Severe Colitis. Gastroenterology, 2009, 136, A-199.	1.3	0
69	Tu1925 MicroRNA Expression in Treatment Naive Active and Inactive Ulcerative Colitis. Gastroenterology, 2012, 142, S-879.	1.3	Ο
70	Sa1923 The Role of Histone Deacetylase Inhibition in Ex Vivo and In Vitro Models of Inflammatory Bowel Diseases. Gastroenterology, 2012, 142, S-360.	1.3	0
71	A man with bloody diarrhoea. BMJ: British Medical Journal, 2012, 344, e978-e978.	2.3	0
72	Mo1728 Cytokine and microRNA Expression in Colonic and Ileal Crohn's Disease Is Modified by Drug Therapy in an Ex Vivo Model. Gastroenterology, 2015, 148, S-695-S-696.	1.3	0

#	Article	IF	CITATIONS
73	Mo1727 Drug Therapies in Ulcerative Colitis Influence the Expression of MicroRNAs and Cytokines in the Sigmoid Mucosa in an Ex Vivo Model. Gastroenterology, 2015, 148, S-695.	1.3	0
74	Sa1830 microRNA23a ls Overexpressed in the Colonic Epithelium in Crohn's Disease. Gastroenterology, 2016, 150, S375.	1.3	0
75	Transcriptomic Profiling of Intestinal Macrophages Isolated from Patients Reveals a Profound Gene Expression Reprogramming Underlying IBD Pathogenesis. Gastroenterology, 2017, 152, S612.	1.3	0
76	A Novel Alternative to Colectomy for Severe Intractable Constipation in Adults: How to Avoid Surgery in Severe Cases?. Archives of Clinical and Medical Case Reports, 2019, 03, .	0.1	0
77	The monitoring and incidence of hyperglycaemia in inflammatory bowel disease patients treated with intravenous steroids. Clinical Medicine, 2019, 19, s20-s20.	1.9	0